NCT05170204 is a phase III multicenter study which will evaluate the efficacy and safety of multiple therapies (alectinib, entrectinib, pralsetinib, and durvalumab) in cohorts of patients with ALK-positive, ROS-1-positive, or RET fusion-positive mutations (respectively) in unresectable Stage III NSCLC. Here, ALK is linked to non-small cell lung carcinoma.